Marlborough biopharma Phio Pharmaceuticals is ushering in a new strategic plan seeking to reposition the company from pure discovery research to full development, utilizing clinical trials.
Phio Pharmaceuticals Corp., a publicly traded biotech firm based in Marlborough, on Thursday named the chairman of its board, Robert Bitterman, to serve as interim executive chairman, leading all aspects of the company’s operations.
The president and CEO of Marlborough biotech company Phio Pharmaceuticals Corp., Gerrit Dispersyn, is stepping down from his role, the firm announced Thursday.
/PRNewswire/ Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its.
/PRNewswire/ Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its.